John Columbus

Statistics

Publications

Citations

427

H-Index

Active since

2004

Affiliations

UCSF Helen Diller Family Comprehensive Cancer Center(Current)

Frederick National Laboratory for Cancer Research

Leidos (United States)

John Columbus is an author at UCSF Helen Diller Family Comprehensive Cancer Center specializing in drug discovery, potency optimization, and tyrosine kinase inhibitors.

Publications per year

2004–2023

Publications

Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity

Jack D. Scott, Duane E. DeMong, Thomas J. Greshock et al. · Journal of Medicinal Chemistry · 2017 · 148 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

A map of WW domain family interactions

Hai Hu, John Columbus, Yi Zhang et al. · PROTEOMICS · 2004 · 136 citations

Life Sciences, Bioinformatics, Molecular Biology +17

Novel tricyclic azepine derivatives: Biological evaluation of pyrimido[4,5-b]-1,4-benzoxazepines, thiazepines, and diazepines as inhibitors of the epidermal growth factor receptor tyrosine kinase

Leon M. Smith, Wai C. Wong, Alexander S. Kiselyov et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 34 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +11

Membrane interactions of the globular domain and the hypervariable region of KRAS4b define its unique diffusion behavior

Debanjan Goswami, De Chen, Yue Yang et al. · eLife · 2020 · 29 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17

Pyrimido-oxazepine as a versatile template for the development of inhibitors of specific kinases

Weitao Pan, Hu Liu, Yong‐Jiang Xu et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 26 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

1–5 of 8